Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran vs ASA in CADASIL
NCT01361763Phase 2Unknown
- Sponsor
- Sant'Andrea Hospital
- Start
- Jun 2011
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of dabigatran in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (2 arms), sponsored by Sant'Andrea Hospital. Primary endpoint: Number of microbleeds on MRI at 6 months. Status: unknown.
02
Drugs
dabigatran
03
Conditions
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Beyond the preview
Go deeper on NCT01361763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01361763.